AbbVie Has A New Cash Cow As Humira Bows To Skyrizi In Third-Quarter Beat
In This Article:
AbbVie stock edged higher Wednesday after the pharma behemoth's new king in immunology finally outpaced its grandfather drug, Humira.
AbbVie stock edged higher Wednesday after the pharma behemoth's new king in immunology finally outpaced its grandfather drug, Humira.